Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK2256098 + trametinib
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GSK2256098 + trametinib is a combination therapy consisting of GSK2256098, an oral focal adhesion kinase (FAK) inhibitor, and trametinib, an oral allosteric MEK1/2 inhibitor. The combination targets two frequently co-activated pathways in cancer: FAK signaling, which plays a role in cancer cell growth and spread, and the MAPK pathway, which is often activated by KRAS mutations. This combination has been studied in advanced solid tumors, particularly pancreatic ductal adenocarcinoma (PDAC) and mesothelioma.
02
Targets
FAK (Focal adhesion kinase)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)
Beyond the preview
Go deeper on GSK2256098 + trametinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK2256098 + trametinib.